Access Pharmaceuticals Presents ProLindac(TM) Data At The AACR-NCI-EORTC Symposium 2008

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that three posters describing significant recent results of the company’s proprietary polymer DACH platinum prodrug, ProLindac, in clinical and preclinical studies are being presented this week at a major international oncology conference held in Geneva, Switzerland.

More: continued here

Filed under: Women's Health / OBGYN on October 27th, 2008